Arbor Rapha Capital Bioholdings Corp. I
ARCK
NASDAQ Global Market11.90
USD
+0.00
- -
CIK
0001855886
CUSIP
03881F104
Return %
Stock
S&P500
1Y
19.36
18.21
3Y
20.81
64.38
5Y
20.81
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ivan Paul Kaufman
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 333 Earle Ovington Blvd Uniondale NY United States of America 11553
- IPO Date
- Jan 28, 2011
- CIK
- 0001855886
- Website
- arcbiocorp.com
- Similar Companies
- Business
- Arbor Rapha Capital Bioholdings Corp. I (ARCK) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting companies in the biotechnology and life sciences sectors. The company offers no specific products or services beyond its SPAC structure, which provides merger and acquisition facilitation services to target entities seeking public market access through de-SPAC transactions; it generates sponsor promote interests and potential future operations post-combination. Headquartered in New York, New York, ARCK was formed in 2024 and conducts its search for targets without geographic limitations, though it emphasizes North American opportunities in innovative biotech therapeutics, diagnostics, and health tech platforms. In a major recent development, ARCK announced its rebranding from its prior identity in late 2025 to reflect its sharpened focus on biotechnology holdings, coinciding with the appointment of key executives specializing in life sciences investments. The company completed a $230 million initial public offering in mid-2024, providing dry powder for potential acquisitions amid a resurgent SPAC market under President Trump's pro-business policies. No business combination has been announced as of December 2025, positioning ARCK to capitalize on biotech funding rounds and strategic alliances in gene editing, AI-driven drug discovery, and regenerative medicine.